The Trump administration intends to terminate federal subsidies for prescription drug plans under Medicare, a program primarily for those over 65, according to a report by the Wall Street Journal. This decision could lead to significant cost increases for around 25 million senior citizens, who rely on these subsidies to manage their prescription expenses.
Citing anonymous officials within the Trump administration, the Wall Street Journal reported that $3.6 billion in subsidies aimed at curbing Medicare insurance premium hikes will end by December. Senior citizens enrolled in these subsidized plans will receive their new premium rates in the fall.
The termination of these subsidies may become a contentious political issue ahead of the November midterm elections, given the importance of prescription drug costs for retirees and those on fixed incomes. The Health policy nonprofit KFF reported that the average premium for a subsidized plan is approximately $36 per month.
According to a Trump administration official, around a quarter of the beneficiaries will see their premiums either decrease or remain unchanged in 2027. Another 30 percent will experience a monthly increase of less than $10, while the remaining 45 percent will face an increase between $11 and $20.
